Medical Technology Breaking News: Aethlon Medical (OTCBB:
AEMD) to Present at Biotech Showcase 2015
SAN DIEGO - January 8, 2015 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCBB:AEMD),
the pioneer in developing targeted therapeutic devices to address infectious
diseases and cancer, today announced that James A. Joyce, Chief Executive
Officer, will present at the Biotech Showcase 2015 Conference on Wednesday,
January 14, 2015.
Details
of Aethlon Medical's presentation are as follows:
Event:
Biotech Showcase 2015
Date:
Wednesday, January 14, 2015
Time:
4:00 p.m. Pacific Time /7:00 p.m. Eastern Time
Location:
Parc 55 Wyndham Union Square, San Francisco, CA
A
live audio webcast of the presentation will be available on the Company's
website (www.aethlonmedical.com) in the Investor
Relations section on the Events and Presentations or can be accessed directly
at http://edge.media-server.com/m/p/4cvayawf.
The
webcast replay will be available approximately two hours after the presentation
ends and will be accessible for one month.
About Biotech Showcase 2015
The
Biotech Showcase 2015 conference takes place January 12-14, 2015, at the Parc
55 Wyndham Hotel located in Union Square, San Francisco, California. Biotech
Showcase is an investor and partnering conference devoted to providing private
and public biotechnology and life sciences companies an opportunity to present
to, and meet with, investors and pharmaceutical executives during the course of
one of the industry's largest annual healthcare investor conferences. Now in
its seventh year, Biotech Showcase is expected to attract upwards of 1,500
attendees.
About Aethlon Medical, Inc.
Aethlon
Medical creates targeted therapeutic devices to address infectious disease,
cancer and neurodegenerative disorders. The company's lead product is the
Aethlon Hemopurifier®, a first-in-class antiviral and immunotherapeutic device
that selectively targets the broad-spectrum elimination of circulating viruses
and tumor-secreted exosomes that promote cancer progression. Exosome Sciences,
Inc. is a majority owned subsidiary that is advancing exosome-based products to
diagnose and monitor cancer, infectious disease and neurological disorders. For
more information, please visit http://www.aethlonmedical.com and connect with
the Company on Twitter, LinkedIn,
Facebook and Google+.
Certain statements herein may be forward-looking and involve
risks and uncertainties. Such forward-looking statements involve assumptions,
known and unknown risks, uncertainties and other factors which may cause the
actual results, performance or achievements of Aethlon Medical, Inc. to be
materially different from any future results, performance, or achievements
expressed or implied by the forward-looking statements. Such potential risks
and uncertainties include, without limitation, that the ESI will not be able to
commercialize its future products, that the FDA will not approve the initiation
of the Company's clinical programs or provide market clearance of the company's
products, future human studies whether revenue or non-revenue generating of the
Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to
improve patient responsiveness to established cancer or hepatitis C therapies
or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense
against viral pathogens, including ebola, the Company's ability to raise
capital when needed, the Company's ability to complete the development of its
planned products, the Company's ability to manufacture its products either
internally or through outside companies and provide its services, the impact of
government regulations, patent protection on the Company's proprietary
technology, the ability of the Company to meet the milestones contemplated in
the DARPA contract, product liability exposure, uncertainty of market
acceptance, competition, technological change, and other risk factors. In such
instances, actual results could differ materially as a result of a variety of
factors, including the risks associated with the effect of changing economic
conditions and other risk factors detailed in the Company's Securities and
Exchange Commission filings. The Company undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated by featured companies, news
submissions, content marketing and online advertising. Contact each company
directly for press release questions. Disclosure is posted on each release if
required but otherwise the news was not compensated for and is published for
the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC
investors should review all OTC and Pink sheet listed companies for adherence
in new disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
